SecBot SecBot
8-K ·Filed Aug 19, 2026

MNOV

MEDICINOVA INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001193125-26-356146
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine employment agreement renewal with no departure, guidance, or financial data, no actionable trading signal. Monitor next 10-Q for any pipeline updates or cash runway changes.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.38
T+0 close · Aug 19, 2026 · via day close
Latest settled
+1.45%
T+60 · $1.40
Vs SPY
+3.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 19 $1.38entry
  2. T+1 · 3mo ago −0.72%α +0.12% · $1.37
  3. T+5 · 3mo ago +7.25%α +7.63% · $1.48
  4. T+20 · 2mo ago +150.00%α +151.95% · $3.45
  5. T+60 · 5d ago +1.45%α +3.00% · $1.40
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MediciNova entered into new executive employment agreements with CEO Yuichi Iwaki and CMO Kazuko Matsuda, formalizing base salaries ($690,246 for Iwaki, $540,143 for Matsuda), target bonuses, and severance terms including change-in-control protections. This is a routine compensation and retention filing with no departure, resignation, or financial results, it does not signal any operational or strategic change.

Key Facts

  • CEO Yuichi Iwaki's annual base salary set at $690,246 with target bonus of 55% of base salary
  • CMO Kazuko Matsuda's annual base salary set at $540,143 with target bonus of 40% of base salary
  • Both executives receive 12-month salary severance on involuntary termination without cause (no change in control)
  • On change-in-control termination: Iwaki gets 24 months salary + 24 months target bonus; Matsuda gets 18 months salary + 18 months target bonus
  • Both executives get 100% accelerated equity vesting on change-in-control termination
  • Agreements supersede prior employment and severance arrangements; no departures or resignations reported

Financial Impact

No material financial impact disclosed; incremental severance obligations are standard for a $66M market cap biotech

compensation expense

Risk Factors

  • No financial or operational data in filing, limited read-through for equity value

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-356146
Document: 0001193125-26-356146-index-headers.html0001193125-26-356146
Document: 0001193125-26-356146-index.html0001193125-26-356146
Document: 0001193125-26-356146.txt0001193125-26-356146

Track record

6 reports on MNOV

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today 8-K Bearish 5/10 Entry $1.35 Now $1.34 +0.74% settles Dec 16
  2. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $1.44 Now $1.34 −6.94% settles Dec 1
  3. Sep 28, 20267w ago Press Release Mixed 5/10 Entry $2.10 to $1.40 Now $1.34 −36.19% ▼ −33.33% −33.30% vs SPY
  4. Sep 24, 20267w ago Press Release Mixed 7/10 Entry $2.65 to $1.41 Now $1.34 −49.43% ▼ −46.79% −46.37% vs SPY
  5. Sep 2, 202610w ago 8-K Bullish 5/10 Entry $1.43 to $1.68 Now $1.34 −6.29% ▲ +17.48% +17.57% vs SPY
  6. Aug 19, 202612w ago 8-K Neutral 2/10 Viewing Entry $1.38 to $3.45 Now $1.34 −2.90% ▲ +150.00% +151.95% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens in 7h 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 19, 2026